Asset Details
Do you wish to reserve the book?
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
Do you wish to request the book?
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
2021
Overview
Background
A primary pulmonary invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive adenocarcinoma of the lung. The prognosis of advanced IMA depending on chemotherapy regimen has not been fully investigated. Here, we compared the clinical outcomes of patients with advanced IMA treated with different palliative chemotherapies that included novel therapeutics.
Methods
This single-center retrospective study included a total of 79 patients diagnosed with IMA and treated with palliative chemotherapy. The primary outcome was the comparison of overall survival according to palliative chemotherapy type. Risk factors associated with death were evaluated as a secondary outcome.
Results
The study cohort of 79 patients comprised 27 progressive or recurrent cases and 52 initial metastatic patients. Thirteen patients (16.5%) received targeted therapy and 18 cases (22.8%) received immunotherapy. When we compared the survival outcomes of the different treatment regimens, patients with IMA treated by immunotherapy (undefined vs. non-immunotherapy 17.0 months,
p
< 0.001) had better overall survival rates. However, there was no difference in the prognosis between the cases treated with a targeted therapy (35.6 vs. non-targeted therapy 17.0 months,
p
= 0.211). None of the conventional regimens produced a better outcome. By multivariable analysis, immunotherapy (HR 0.28; 95% CI 0.11–0.74;
P
= 0.008) was found to be an independent prognostic factor for death.
Conclusions
This study suggests that immunotherapy for patients with advanced IMA may provide favorable outcomes than other chemotherapy options.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
